News

The objective of the pilot study is to evaluate the safety and feasibility of the Neuro-Spinal Scaffold as well as to gather preliminary evidence of effectiveness. Dr. Nicholas

Jean-Philippe Langevin, M.D., an expert in neurotrauma and a neurosurgeon at the Veterans Affairs Greater Los Angeles (VAGLA) medical center, will lead the study as Principal Investigator. The

The company also announced the establishment of its corporate headquarters in Cambridge, Massachusetts, where Patrick Anquetil, Ph.D., MBA and Mark Philip, Ph.D., MBA serve as chief executive officer

Ofev is a kinase inhibitor that blocks multiple pathways that may be involved in the scarring of lung tissue and these capsules will be available to patients within

Esbriet is an oral medicine and is believed to interfere with the production of transforming growth factor (TGF) beta, a small protein in the body involved in the

The results show that AG014 is safe and well tolerated while providing localized gastro-intestinal (GI) exposure. AG014 is the company’s ActoBiotics delivery platform and works by expressing and

Data from this randomized, double-blind, placebo-controlled, cross-over study demonstrated that duvelisib was well tolerated and met several secondary and exploratory endpoints in an allergen challenge study. Clinical improvement

Amitiza is a prostone and is a locally acting chloride channel activator, indicated in the US to treat chronic idiopathic constipation (CIC) in adults and opioid-induced constipation (OIC)

Discovered and developed by Eisai, lenvatinib is an oral multiple receptor tyrosine kinase inhibitor with a unique binding mode that selectively inhibits the kinase activities of vascular endothelial